Summary
3.24 0.14(4.52%)09/27/2024
Codexis Inc. (CDXS)
Codexis Inc. (CDXS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 4.22 | 4.18 | 8.00 | 7.82 | -7.95 | 109.03 | -76.33 | -75.57 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 3.24 | |
| Open | 3.17 | |
| High | 3.30 | |
| Low | 3.14 | |
| Volume | 517,966 | |
| Change | 0.13 | |
| Change % | 4.22 | |
| Avg Volume (20 Days) | 641,341 | |
| Volume/Avg Volume (20 Days) Ratio | 0.81 | |
| 52 Week Range | 1.50 - 4.90 | |
| Price vs 52 Week High | -33.88% | |
| Price vs 52 Week Low | 116.00% | |
| Range | 2.21 | |
| Gap Up/Down | 0.02 | |
Fundamentals | ||
| Market Capitalization (Mln) | 220 | |
| EBIDTA | -37,792,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -1.1600 | |
| WallStreet Target Price | 6.57 | |
| Book Value | 1.1230 | |
| Earnings Per Share | -0.9400 | |
| EPS Estimate Current Quarter | -0.1800 | |
| EPS Estimate Next Quarter | -0.2000 | |
| EPS Estimate Current Year | -0.6700 | |
| EPS Estimate Next Year | -0.7500 | |
| Diluted EPS (TTM) | -0.9400 | |
| Revenues | ||
| Profit Marging | -0.8773 | |
| Operating Marging (TTM) | -0.6963 | |
| Return on asset (TTM) | -0.1465 | |
| Return on equity (TTM) | -0.6345 | |
| Revenue TTM | 74,234,000 | |
| Revenue per share TTM | 1.0740 | |
| Quarterly Revenue Growth (YOY) | 0.3150 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 20,458,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 138.8889 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 2.3376 | |
| Revenue Enterprise Value | 2.1867 | |
| EBITDA Enterprise Value | -3.4178 | |
| Shares | ||
| Shares Outstanding | 70,557,600 | |
| Shares Float | 63,674,685 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.04 | |
| Insider (%) | 2.06 | |
| Institutions (%) | 80.09 | |
09/06 16:05 EST - globenewswire.com
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 4,950 shares of Codexis common stock and (ii) 8,125 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan.
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to three new employees as approved by the Compensation Committee of Codexis' Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 4,950 shares of Codexis common stock and (ii) 8,125 restricted stock units (RSUs) as inducement awards under the company's 2024 Inducement Plan.
09/03 16:05 EST - globenewswire.com
Codexis to Participate in Upcoming Healthcare Conferences
REDWOOD CITY, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that management will participate in two upcoming investor conferences.
Codexis to Participate in Upcoming Healthcare Conferences
REDWOOD CITY, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that management will participate in two upcoming investor conferences.
08/20 16:05 EST - globenewswire.com
Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting
REDWOOD CITY, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a presentation and panel discussion at the upcoming RNA Leaders annual meeting, being held September 4-5, 2024, in San Diego, CA. The Company's presentations will focus on the use of enzymes to drive the scalable and cost-effective manufacture of short inhibitory ribonucleic acid (siRNA) duplexes.
Codexis to Participate in Enzymatic Synthesis Presentations at RNA Leaders Annual Meeting
REDWOOD CITY, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a presentation and panel discussion at the upcoming RNA Leaders annual meeting, being held September 4-5, 2024, in San Diego, CA. The Company's presentations will focus on the use of enzymes to drive the scalable and cost-effective manufacture of short inhibitory ribonucleic acid (siRNA) duplexes.
08/15 16:05 EST - globenewswire.com
Codexis Publishes FY2023 Sustainability Disclosures
Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board
Codexis Publishes FY2023 Sustainability Disclosures
Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board Inaugural ESG Disclosures Align with the Sustainability Accounting Standards Board
08/08 23:01 EST - seekingalpha.com
Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Carrie McKim - Director, IR Stephen Dilly - President and CEO Stefan Lutz - SVP, Research Kevin Norrett - COO Sri Ryali - CFO Conference Call Participants Matt Stanton - Jefferies Operator Welcome to the Codexis Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Codexis, Inc. (CDXS) Q2 2024 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Carrie McKim - Director, IR Stephen Dilly - President and CEO Stefan Lutz - SVP, Research Kevin Norrett - COO Sri Ryali - CFO Conference Call Participants Matt Stanton - Jefferies Operator Welcome to the Codexis Second Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
08/08 18:56 EST - zacks.com
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.17 per share a year ago.
Codexis (CDXS) Reports Q2 Loss, Tops Revenue Estimates
Codexis (CDXS) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.26. This compares to loss of $0.17 per share a year ago.
07/18 16:05 EST - globenewswire.com
Codexis to Report Second Quarter 2024 Financial Results on August 8
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.
Codexis to Report Second Quarter 2024 Financial Results on August 8
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.
07/01 16:05 EST - globenewswire.com
Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company's investigational Fabry and Pompe disease compounds. Under the terms of the agreement, Codexis is eligible to receive future development and commercial milestone payments in addition to a low-to-mid single-digit percentage net sales-based royalty.
Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company's investigational Fabry and Pompe disease compounds. Under the terms of the agreement, Codexis is eligible to receive future development and commercial milestone payments in addition to a low-to-mid single-digit percentage net sales-based royalty.
05/22 16:25 EST - globenewswire.com
Codexis to Participate in Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 5-6, 2024, in New York, New York.
Codexis to Participate in Jefferies Global Healthcare Conference
REDWOOD CITY, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 5-6, 2024, in New York, New York.
05/20 16:05 EST - globenewswire.com
Codexis to Participate in TD Cowen 2nd Annual Sustainability Week
REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, “Sustainable API Manufacturing” at the TD Cowen 2nd Annual Sustainability Week, being held virtually May 21-23, 2024. During the presentation, Management will highlight the potential benefits of an enzymatic route of synthesis in the manufacture of small molecule and siRNA therapeutics.
Codexis to Participate in TD Cowen 2nd Annual Sustainability Week
REDWOOD CITY, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will participate in a panel discussion titled, “Sustainable API Manufacturing” at the TD Cowen 2nd Annual Sustainability Week, being held virtually May 21-23, 2024. During the presentation, Management will highlight the potential benefits of an enzymatic route of synthesis in the manufacture of small molecule and siRNA therapeutics.
05/14 06:00 EST - globenewswire.com
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Data highlighting this historic manufacturing milestone are being presented today in a Spotlight Presentation at the TIDES USA annual meeting taking place in Boston, MA, and virtually May 14 – 17, 2024.
Codexis Presents Groundbreaking Enzymatic Synthesis Data at TIDES USA Annual Meeting
REDWOOD CITY, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has successfully synthesized an oligonucleotide via an enzymatic route to support RNA-based therapeutics manufacturing. Data highlighting this historic manufacturing milestone are being presented today in a Spotlight Presentation at the TIDES USA annual meeting taking place in Boston, MA, and virtually May 14 – 17, 2024.
05/02 20:24 EST - seekingalpha.com
Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Carrie McKim - Director, Investor Relations Stephen Dilly - President & Chief Executive Officer Stefan Lutz - Senior Vice President, Research Kevin Norrett - Chief Operating Officer Sri Ryali - Chief Financial Officer Conference Call Participants Matt Stanton - Jefferies Evan Stampler - Stifel Matt Hewitt - Craig-Hallum Operator Welcome to the Codexis' First Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is being recorded.
Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript
Codexis, Inc. (NASDAQ:CDXS ) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Carrie McKim - Director, Investor Relations Stephen Dilly - President & Chief Executive Officer Stefan Lutz - Senior Vice President, Research Kevin Norrett - Chief Operating Officer Sri Ryali - Chief Financial Officer Conference Call Participants Matt Stanton - Jefferies Evan Stampler - Stifel Matt Hewitt - Craig-Hallum Operator Welcome to the Codexis' First Quarter 2024 Earnings Call. [Operator Instructions] Please note this event is being recorded.
04/18 16:05 EST - globenewswire.com
Codexis to Report First Quarter 2024 Financial Results on May 2
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on Thursday, May 2, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.
Codexis to Report First Quarter 2024 Financial Results on May 2
REDWOOD CITY, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2024 on Thursday, May 2, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company's financial results and provide a business update.
04/11 07:05 EST - globenewswire.com
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platform Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platform
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platform Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis™ manufacturing platform
02/28 22:39 EST - seekingalpha.com
Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript
Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript
Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript
Codexis, Inc. (CDXS) Q4 2023 Earnings Call Transcript
02/28 19:51 EST - zacks.com
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
Codexis (CDXS) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.19 per share a year ago.
Codexis (CDXS) Tops Q4 Earnings and Revenue Estimates
Codexis (CDXS) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.16 per share. This compares to loss of $0.19 per share a year ago.
02/28 16:05 EST - globenewswire.com
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Around End of 2026 2024 to Focus on Securing Early Access Customers for ECO Synthesis™ Manufacturing Platform, Launch of Double-stranded RNA Ligase and Return to Growth for Pharmaceutical Manufacturing REDWOOD CITY, Calif.
Codexis Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID™ Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Around End of 2026 2024 to Focus on Securing Early Access Customers for ECO Synthesis™ Manufacturing Platform, Launch of Double-stranded RNA Ligase and Return to Growth for Pharmaceutical Manufacturing REDWOOD CITY, Calif.
02/26 16:05 EST - globenewswire.com
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company's newly engineered double-stranded DNA (dsDNA) ligase for next-generation sequencing (NGS) library preparation and the Company's EvoT4™ DNA ligase. Under the terms of the deal, Codexis will receive upfront and technical milestone payments. This deal supersedes the prior exclusive license on the EvoT4™ DNA ligase.
Codexis Enters Exclusive Licensing Agreement for Newly Engineered Double-Stranded DNA Ligase with Roche
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company's newly engineered double-stranded DNA (dsDNA) ligase for next-generation sequencing (NGS) library preparation and the Company's EvoT4™ DNA ligase. Under the terms of the deal, Codexis will receive upfront and technical milestone payments. This deal supersedes the prior exclusive license on the EvoT4™ DNA ligase.
02/26 08:05 EST - globenewswire.com
Codexis to Participate in TD Cowen 44th Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual Health Care Conference, being held March 4-6, 2024, in Boston, Massachusetts.
Codexis to Participate in TD Cowen 44th Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44th Annual Health Care Conference, being held March 4-6, 2024, in Boston, Massachusetts.